Navigation Links
Study eyes fluoxetine in recreational waters
Date:11/18/2010

Mercyhurst College's research of contaminants in the recreational waters at Presque Isle State Park got a $250,000 boost from the U.S. Environmental Protection Agency, it was announced today.

The funds, awarded to Mercyhurst in collaboration with the Regional Science Consortium and Penn State Behrend, will be used to identify and quantify chemicals in the water with important human and environmental health implications. Dr. Steven Mauro, assistant professor of biology, is directing the research at Mercyhurst.

One chemical that Mauro's team of biology students at Mercyhurst has targeted is fluoxetine, an anti-depressant. It has been identified in elevated concentrations at two locations along Elk Creek and Walnut Creek and at beaches 1, 2, 6 and 10.

"Our current data reveals the presence of fluoxetine at levels nonthreatening to animals or humans, but quite capable of killing microbes, like bacteria and viruses, that are important to the viability of any aquatic area," Mauro said. "What gives us reason for concern and why we want to focus more studies on fluoxetine is that it is more lethal to E. coli than other types of bacteria we have thus far tested."

E.coli has the potential to be pathogenic to humans, so the ability of fluoxetine to remove E.coli from these waters may be positive for human safety. However, since the safety of Presque Isle's recreational waters to the swimming public is typically gauged by E.coli levels, Mauro suggested the possibility that fluoxetine could be lowering the E. coli numbers and giving a false impression that the waters are safer than they are.

He said continued studies of fluoxetine, including its interaction with other chemicals and its impact on bacteria like E. coli, are needed to draw relevant, actionable conclusions. While Mercyhurst will conduct much of the actual on-site research, Mauro said faculty from Penn State Behrend and the Regional Science Consortium will aid in th
'/>"/>

Contact: Debbie Morton
dmorton@mercyhurst.edu
814-824-2552
Mercyhurst College
Source:Eurekalert

Page: 1 2

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. £2 million study to reveal workings of dementia genes
3. New study looks to define evangelicals and how they affect polling
4. CU-Boulder study suggests air quality regulations miss key pollutants
5. Researchers study acoustic communication in deep-sea fish
6. Study reveals homeowner perceptions in fire-prone areas
7. Researchers study how pistachios may improve heart health
8. Study: urban black bears live fast, die young
9. New study indicates link between weight gains during pregnancy and dieting history
10. Study reveals specific gene in adolescent men with delinquent peers
11. Sweat it out: UH study examines ability of sweat patches to monitor bone loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... for prostate cancer in men may get a second life ... common form of cancer in women worldwide, scientists are reporting ... Chemistry . Chien Chou and colleagues say that the ... potential biomarker of breast cancer in women. However, levels of ...
... were to escape from captivity they could succeed in ... researchers have found. Their research, published in Evolutionary ... salmon as they are considered for commercial farming. ... been of interest to the aquaculture industry and now ...
... German . Plants, too, have an immune system ... and the subsequent immune response, in particular at the cell ... cause plant diseases have their weapons, too. Some are able ... particularly ingenious attacker, powdery mildew, can even reprogram cells in ...
Cached Biology News:First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2TUM researchers discover a new switch in resistance to plant diseases 2
(Date:5/22/2015)... 22, 2015  Actavis plc (NYSE: ACT ) ... of Appeals for the Second Circuit has issued a ... the Company to continue distribution of NAMENDA ® ... http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   "While we are disappointed ... intend to continue our strong efforts to convey the ...
(Date:5/21/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... and commercializes proprietary technologies and products for advanced microarray ... the second fiscal quarter ended March 31, 2015. ... advance business with our existing customers and to develop ... CEO of SQI. "The delivery of a fully automated ...
(Date:5/21/2015)... 21, 2015 uBiome, the leading ... partnership with PicnicHealth, a healthcare company that collects ... with Inflammatory Bowel Disease (IBD) will receive a ... uBiome research kit. Both companies were funded by ... , For more information on this partnership and ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
Breaking Biology Technology:Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today ... 1 safety study of Sangamo,s zinc finger nuclease (ZFN) based ... the internet. , Data were presented in a student course ... single subject treated with SB-728-T who, as part of the ...
... Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... development company that identifies and advances a diverse portfolio ... announced that results from a study evaluating nimotuzumab were ... Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. ...
... , BALTIMORE, Nov. 18 Champions Biotechnology, ... development company with a predictive preclinical platform aimed at ... drugs, has established an exclusive licensing agreement with Yale ... Bithionol for cancer treatment. Scientists from Yale and ...
Cached Biology Technology:Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 4
... NAP-10 Columns, 50. For rapid and ... 10-mers) in less than 15 minutes by ... in distilled water containing 0.15% Kathon CG/ICP ... volume: 0.5 ml (NAP-5), 1 ml ...
Human Serpin A3 MAb (Clone 213907)...
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Mouse Semaphorin 6B MAb (Clone 256537)...
Biology Products: